AGL — agilon health, inc.
Is AGL overbought or oversold? Here is the current MarketMoodz read.
agilon health, inc. (AGL) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Medical Care Facilities) last closed at $115.20. The rating moved from Neutral to Overbought on November 6, 2026.
- Public ratingOverbought (as of November 17, 2026)
- Last close$115.20
- Last changeMoved from Neutral to Overbought on November 6, 2026
- SectorHealthcare
- IndustryMedical Care Facilities
See all overbought Healthcare stocks →
AI analysis
agilon health, inc. (AGL) operates in a structurally favorable Medicare Advantage market with predictable capitated cash flows and strong provider-alignment advantages, but recent CMS program-integrity proposals materially raise near-term regulatory and reconciliation risk. Financial performance is contingent on accurate risk-adjustment, utilization management and disciplined cost control; upside drivers include steady enrollment growth, local-market provider partnerships and any favorable regulatory clarifications or strategic transactions. Downside scenarios center on clawbacks, elevated compliance costs and competitive benefit subsidies that compress margins. Given the balanced mix of durable demand and heightened policy risk, near-term outlook is cautious with close monitoring of CMS guidance, upcoming earnings and enrollment / RADV developments.
Key factors
- Medicare Advantage focus with stable and growing enrollment demographic tailwinds from an aging population
- Capitated revenue model provides predictability but is sensitive to utilization, coding accuracy and risk adjustment outcomes
- Strategic partnerships with physician groups and local market presence support member retention and care coordination advantages
- Recent CMS proposals increasing program integrity (RADV and anti-billing measures) raise near-term regulatory scrutiny and compliance costs
- Defensive sector flows into large-cap healthcare and payer stability partially offset cyclical volatility in broader equity markets
- Potential for M&A or strategic consolidation in the MA space could be a multi-quarter catalyst if executed attractively
Risks
- CMS anti-fraud and RADV tightening could lead to material clawbacks or higher compliance/verification expense and compress margins
- Adverse changes in reimbursement, benefit design or MLR requirements that reduce profitability of aggressive $0‑premium benefit offerings
- Higher-than-expected utilization or unfavorable risk score reconciliation could weaken cash flows and earnings
- Competitive pressure from larger vertically integrated payors or new entrants offering subsidized premiums and benefits
- Operational execution risk in managing growth, provider network relationships and claims/risk adjustment accuracy
- Market perception volatility on regulatory headlines or earnings that could drive outsized short-term share moves
Latest MarketMoodz coverage
See today's live rating, score and targets
Members see the live hourly rating for AGL — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.